MedTrace Logo

Safety and Efficacy Study of Pitavastatin in Patient With a Metabolic Syndrome

NCT00640276 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 187

Last updated 2012-03-30

No results posted yet for this study

Summary

We will identify the influence of long-term treatment of Pitavastatin compared to non-treatment control group on the metabolic syndrome by evaluation of a change of metabolic syndrome component score. And we will additionally observe the changes of CVD risk factors like lipid profile, abdominal fat, insulin resistance and so on.

Conditions

Interventions

DRUG

pitavastatin

Pitavastatin 2mg daily once

BEHAVIORAL

Lifestyle Modification

conducting mainly exercises and diet

Sponsors & Collaborators

Principal Investigators

  • Chang Beom Lee · Hanyang Univ. Guri Hospital

  • Hak Chul Jang · Seoul National University Bundang Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2011-02-28
Completion
2011-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00640276 on ClinicalTrials.gov